Diagnosis and management of acute graft-versus-host disease

British Journal of Haematology

Volumn 158, Issue 1, 2012, Pages 30-45

  Dignan, Fiona L ^a,b   Clark, Andrew ^c   Amrolia, Persis ^d   Cornish, Jacqueline ^e   Jackson, Graham ^f   Mahendra, Prem ^g   Scarisbrick, Julia J ^g   Taylor, Peter C ^h   Hadzic, Nedim ⁱ   Shaw, Bronwen E ^a,j   Potter, Michael N ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^f Hospital   (United Kingdom)

^g UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^h ROTHERHAM GENERAL HOSPITAL   (United Kingdom)

ⁱ KING S COLLEGE HOSPITAL   (United Kingdom)

^j Anthony Nolan   (United Kingdom)

more..

Author keywords

Acute graft versus host disease; AGvHD; Diagnosis; Management; Transplant

Indexed keywords

ALEMTUZUMAB; ANTIHISTAMINIC AGENT; BASILIXIMAB; BECLOMETASONE; BETAMETHASONE VALERATE; BUDESONIDE; CALCINEURIN INHIBITOR; CLOBETASOL PROPIONATE; CLOBETASONE BUTYRATE; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; DENILEUKIN DIFTITOX; ELAFIN; ETANERCEPT; HYDROCORTISONE; INFLIXIMAB; INOLIMOMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; METHOXSALEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; DEVICES; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRACORPOREAL PHOTOPHERESIS; EYE; GASTROINTESTINAL TRACT; GENITAL SYSTEM; HEMOLYTIC UREMIC SYNDROME; HUMAN; LIVER; LOW DRUG DOSE; LUNG; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUTH; NEUROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PHAGOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; PUVA; RECOMMENDED DRUG DOSE; SEIZURE; SKIN; SKIN BIOPSY; SURVIVAL RATE; TISSUE DISTRIBUTION;

ACUTE DISEASE; BONE MARROW TRANSPLANTATION; DISEASE MANAGEMENT; GRAFT VS HOST DISEASE; HUMANS; STEM CELL TRANSPLANTATION;

EID: 84862241567     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09129.x     Document Type: Article

References (137)

1. Akpek, G., Boitnott, J.K., Lee, L.A., Hallick, J.P., Torbenson, M., Jacobsohn, D.A., Arai, S., Anders, V. & Vogelsang, G.B. (2002) Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood, 100, 3903-3907.
2. Allison, A.C. & Eugui, E.M. (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 47, 85-118.
3. Alousi, A.M., Weisdorf, D.J., Logan, B.R., Bolaños-Meade, J., Carter, S., Difronzo, N., Pasquini, M., Goldstein, S.C., Ho, V.T., Hayes-Lattin, B., Wingard, J.R., Horowitz, M.M. & Levine, J.E. Blood and Marrow Transplant Clinical Trials Network (2009) Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood, 114, 511-517.
4. Anasetti, C., Hansen, J.A., Waldmann, T.A., Appelbaum, F.R., Davis, J., Deeg, H.J., Doney, K., Martin, P.J., Nash, R., Storb, R., Sullivan, K., Witherspoon, R.P., Binger, M., Chizzonite, R., Hakimi, J., Mould, D., Satoh, H. & Light, S.E. (1994) Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood, 84, 1320-1327.
5. Arai, S., Margolis, J., Zahurak, M., Anders, V. & Vogelsang, G.B. (2002) Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biology of Blood and Marrow Transplantation, 8, 155-160.
6. Basara, N., Kiehl, M.G., Blau, W., Römer, E., Bischoff, M., Schmetzer, B., Kirsten, D., Günzelmann, S. & Fauser, A.A. (2001) Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplant Proceedings, 33, 2121-2123.
7. Bay, J.O., Dhédin, N., Goerner, M., Vannier, J.P., Marie-Cardine, A., Stamatoullas, A., Jouet, J.P., Yakoub-Agha, I., Tabrizi, R., Faucher, C., Diez-Martin, J.L., Nunez, G., Parody, R., Milpied, N., Espérou, H., Garban, F., Galambrun, C., Kwiatkovski, F., Darlavoix, I., Zinaï, A., Fischer, A., Michallet, M. & Vernant, J.P. (2005) Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation, 80, 782-788.
8. Benito, A.I., Furlong, T., Martin, P.J., Anasetti, C., Appelbaum, F.R., Doney, K., Nash, R.A., Papayannopoulou, T., Storb, R., Sullivan, K.M., Witherspoon, R. & Deeg, H.J. (2001) Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation, 72, 1924-1929.
9. Bertz, H., Afting, M., Kreisel, W., Duffner, U., Greinwald, R. & Finke, J. (1999) Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplantation, 24, 1185-1189.
10. Bladon, J. & Taylor, P.C. (2006) Extracorporeal photopheresis: a focus on apoptosis and cytokines. Journal of Dermatological Science, 43, 85-94.
11. Bolaños-Meade, J., Jacobsohn, D.A., Margolis, J., Ogden, A., Wientjes, M.G., Byrd, J.C., Lucas, D.M., Anders, V., Phelps, M., Grever, M.R. & Vogelsang, G.B. (2005) Pentostatin in steroid-refractory acute graft-versus-host disease. Journal of Clinical Oncology, 23, 2661-2668.
12. Bordigoni, P., Dimicoli, S., Clement, L., Baumann, C., Salmon, A., Witz, F. & Feugier, P. (2006) Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. British Journal of Haematology, 135, 382-385.
13. Busca, A., Locatelli, F., Marmont, F., Ceretto, C. & Falda, M. (2007) Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 82, 45-52.
14. Byun, H.J., Yang, J.I., Kim, B.K. & Cho, K.H. (2011) Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions. Journal of the American Academy of Dermatology, 65, 726-732.
15. Cahn, J.Y., Klein, J.P., Lee, S.J., Milpied, N., Blaise, D., Antin, J.H., Leblond, V., Ifrah, N., Jouet, J.P., Loberiza, F., Ringden, O., Barrett, A.J., Horowitz, M.M. & Socié, G. (2005) Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood, 106, 1495-1500.
16. Carella, A.M., Beltrami, G., Scalzulli, P.R., Carella, Jr, A.M. & Corsetti, M.T. (2004) Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGvHD). Bone Marrow Transplantation, 33, 131-132.
17. Couriel, D., Saliba, R., Hicks, K., Ippoliti, C., de Lima, M., Hosing, C., Khouri, I., Andersson, B., Gajewski, J., Donato, M., Anderlini, P., Kontoyiannis, D.P., Cohen, A., Martin, T., Giralt, S. & Champlin, R. (2004) Tumor necrosis factor-alpha blockade for the treatment of aGvHD. Blood, 104, 649-654.
18. Couriel, D.R., Saliba, R., de Lima, M., Giral, S., Andersson, B., Khouri, I., Hosing, C., Ippoliti, C., Shpall, E.J., Champlin, R. & Alousi, A. (2009) A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 15, 1555-1562.
19. Cragg, L., Blazar, B.R., Defor, T., Kolatker, N., Miller, W., Kersey, J., Ramsay, M., McGlave, P., Filipovich, A. & Weisdorf, D. (2000) A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 6, 441-447.
20. Cruz-Correa, M., Poonawala, A., Abraham, S.C., Wu, T.T., Zahurak, M., Vogelsang, G., Kalloo, A.N. & Lee, L.A. (2002) Endoscopic findings predict the histologic diagnosis in gastrointestinal graft-versus-host disease. Endoscopy, 34, 808-813.
21. Dall'Amico, R. & Messina, C. (2002) Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Therapeutic Apheresis, 6, 296-304.
22. Das-Gupta, E., Watson, J., Byrne, J. & Russell, N. (2011) A single centre experience of the efficacy of extracorporeal photopheresis in the treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplantation, 46, S114.
23. Deeg, H.J. (2007) How I treat refractory aGvHD. Blood, 109, 4119-4126.
24. Devergie, A. (2008) Graft versus host disease, chapter 11. In: ESH-EBMT Handbook, (eds J. Apperley, E. Carreras, E. Gluckman, A. Grat-wohl & T. Masszi), pp. 218-236. Forum Service Editore, Genoa, Italy.
25. Dignan, F.L., Amrolia, P., Clark, A., Cornish, J., Jackson, G., Mahendra, P., Scarisbrick, J.J., Taylor, P.C., Shaw, B.E. & Potter, M.N. on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology and the British Society for Blood and Marrow Transplantation (2012a) Diagnosis and management of chronic graft-versus-host disease. British Journal of Haematology, 158, 46-61.
26. Dignan, F.L., Scarisbrick, J.J., Cornish, J., Clark, A., Amrolia, P., Jackson, G., Mahendra, P., Taylor, P.C., Shah, P., Lightman, S., Fortune, F., Kibbler, C., Andreyev, J., Albanese, A., Hadzic, N., Potter, M.N. & Shaw, B.E. on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology and the British Society for Blood and Marrow Transplantation (2012b) BCSH guideline: Organ-specific management and supportive care in graft-versus-host disease. British Journal of Haematology, 158, 62-78.
27. Duarte, R.F., Delgado, J., Shaw, B.E., Wrench, D.J., Ethell, M., Patch, D., Dhillon, A.P., Mackinnon, S., Potter, M.N. & Quaglia, A.F. (2005) Histologic features of the liver biopsy predict the clinical outcome for patients with graft-versus-host disease of the liver. Biology of Blood and Marrow Transplantation, 11, 805-813.
28. Ferrara, J.L. & Deeg, H.J. (1991) Graft-versus-host disease. New England Journal of Medicine, 324, 667-674.
29. Ferrara, J.L., Levine, J.E., Reddy, P. & Holler, E. (2009) Graft-versus-host disease. Lancet, 373, 1550-1561.
30. Filipovich, A.H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J.R., Lee, S.J., Martin, P., Chien, J., Przepiorka, D., Couriel, D., Cowen, E.W., Dinndorf, P., Farrell, A., Hartzman, R., Henslee-Downey, J., Jacobsohn, D., McDonald, G., Mittleman, B., Rizzo, J.D., Robinson, M., Schubert, M., Schultz, K., Shulman, H., Turner, M., Vogelsang, G. & Flowers, M.E. (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biology of Blood and Marrow Transplantation, 11, 945-956.
31. Firoz, B.F., Lee, S.J., Nghiem, P. & Qureshi, A.A. (2006) Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis. Archives of Dermatology, 142, 175-182.
32. Foss, F.M. (2006) The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation. Seminars in Hematology, 43, S35-S43.
33. Fujii, N., Takenaka, K., Shinagawa, K., Ikeda, K., Maeda, Y., Sunami, K., Hiramatsu, Y., Matsuo, K., Ishimaru, F., Niiya, K., Yoshino, T., Hirabayashi, N. & Harada, M. (2001) Hepatic graft-versus-host disease presenting as an acute hepatitis after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplantation, 27, 1007-1010.
34. Funke, V.A., de Medeiros, C.R., Setúbal, D.C., Ruiz, J., Bitencourt, M.A., Bonfim, C.M., Neto, J.Z. & Pasquini, R. (2006) Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplantation, 37, 961-965.
35. Furlong, T., Storb, R., Anasetti, C., Appelbaum, F.R., Deeg, H.J., Doney, K., Martin, P., Sullivan, K., Witherspoon, R. & Nash, R.A. (2000) Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplantation, 26, 985-991.
36. Furlong, T., Martin, P., Flowers, M.E., Carnevale-Schianca, F., Yatscoff, R., Chauncey, T., Appelbaum, F.R., Deeg, H.J., Doney, K., Witherspoon, R., Storer, B., Sullivan, K.M., Storb, R. & Nash, R.A. (2009) Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplantation, 44, 739-748.
37. Ghez, D., Rubio, M.T., Maillard, N., Suarez, F., Chandesris, M.O., Delarue, R., Deau-Fischer, B., Varet, B., Hermine, O. & Buzyn, A. (2009) Rapamycin for refractory acute graft-versus-host disease. Transplantation, 88, 1081-1087.
38. Glucksberg, H., Storb, R., Fefer, A., Buckner, C.D., Neiman, P.E., Clift, R.A., Lerner, K.G. & Thomas, E.D. (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation, 18, 295-304.
39. Goker, H., Haznedaroglu, I.C. & Chao, N.J. (2001) Acute graft-vs-host disease: pathobiology and management. Experimental Hematology, 29, 259-277.
40. Gómez-Almaguer, D., Ruiz-Argüelles, G.J., del Carmen Tarín-Arzaga, L., González-Llano, O., Gutiérrez-Aguirre, H., Cantú-Rodríguez, O., Jaime-Pérez, J., Carrasco-Yalán, A. & Giralt, S. (2008) Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 14, 10-15.
41. Gratwohl, A., Hermans, J., Apperley, J., Arcese, W., Bacigalupo, A., Bandini, G., di Bartolomeo, P., Boogaerts, M., Bosi, A., Carreras, E., Devergie, A., Ferrant, A., Fibbe, W.E., Frassoni, F., Gahrton, G., Goldman, J., Iriondo, A., Jacobsen, J., Kolb, H.J., Link, H., Michallet, M., Prentice, H.G., Reiffers, J., Rhee, F.V., Ruutu, T., Schwaighofer, H., Vernant, J.P., de Witte, T. & Niederwieser, D. (1995) Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood, 86, 813-818.
42. Greinix, H.T., Volc-Platzer, B., Rabitsch, W., Gmeinhart, B., Guevara-Pineda, C., Kalhs, P., Krutmann, J., Hönigsmann, H., Ciovica, M. & Knobler, R.M. (1998) Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood, 92, 3098-3104.
43. Greinix, H.T., Knobler, R.M., Worel, N., Schneider, B., Schneeberger, A., Hoecker, P., Mitterbauer, M., Rabitsch, W., Schulenburg, A. & Kalhs, P. (2006) The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica, 91, 405-408.
44. Hale, G. (2001) The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy, 3, 137-143.
45. Hattori, K., Hirano, T., Miyajima, H., Yamakawa, N., Tateno, M., Oshimi, K., Kayagaki, N., Yagita, H. & Okumura, K. (1998) Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood, 91, 4051-4055.
46. Hervé, P., Flesch, M., Tiberghien, P., Wijdenes, J., Racadot, E., Bordigoni, P., Plouvier, E., Stephan, J.L., Bourdeau, H. & Holler, E. (1992) Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood, 79, 3362-3368.
47. Hettiaratchy, S. & Papini, R. (2004) Initial management of a major burn: II-assessment and resuscitation. British Medical Journal, 329, 101-103.
48. Hings, I.M., Filipovich, A.H., Miller, W.J., Blazar, B.L., McGlave, P.B., Ramsay, N.K., Kersey, J.H. & Weisdorf, D.J. (1993) Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. Transplantation, 56, 577-580.
49. Ho, V.T., Zahrieh, D., Hochberg, E., Micale, E., Levin, J., Reynolds, C., Steckel, S., Cutler, C., Fisher, D.C., Lee, S.J., Alyea, E.P., Ritz, J., Soiffer, R.J. & Antin, J.H. (2004) Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood, 104, 1224-1226.
50. Hockenbery, D.M., Cruickshank, S., Rodell, T.C., Gooley, T., Schuening, F., Rowley, S., David, D., Brunvand, M., Berryman, B., Abhyankar, S., Bouvier, M. & McDonald, G.B. (2007) A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood, 109, 4557-4563.
51. Hoda, D., Pidala, J., Salgado-Vila, N., Kim, J., Perkins, J., Bookout, R., Field, T., Perez, L., Ayala, E., Ochoa-Bayona, J.L., Raychaudhuri, J., Alsina, M., Greene, J., Janssen, W., Fernandez, H.F., Anasetti, C. & Kharfan-Dabaja, M.A. (2010) Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplantation, 45, 1347-1351.
52. Hsu, B., May, R., Carrum, G., Krance, R. & Przepiorka, D. (2001) Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transplantation, 28, 945-950.
53. Huang, X.J., Jiang, Q., Chen, H., Xu, L., Liu, D., Chen, Y., Han, W., Zhang, Y., Liu, K. & Lu, D. (2005) Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 36, 343-348.
54. Ibrahim, R.B., Abidi, M.H., Cronin, S.M., Lum, L.G., Al-Kadhimi, Z., Ratanatharathorn, V. & Uberti, J.P. (2009) Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease. Biology of Blood and Marrow Transplantation, 15, 395-405.
55. Inagaki, J., Nagatoshi, Y., Hatano, M., Isomura, N., Sakiyama, M. & Okamura, J. (2008) Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children. Bone Marrow Transplantation, 41, 571-577.
56. Iyer, R.V., Hahn, T., Roy, H.N., Battiwalla, M., Cooper, M., Anderson, B., Paplham, P., Brown, K., Bambach, B., Segal, B.H. & McCarthy, Jr, P.L. (2005) Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease. Biology of Blood and Marrow Transplantation, 11, 587-592.
57. Kamble, R., Oholendt, M. & Carrum, G. (2006) Rituximab responsive refractory acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 12, 1201-1202.
58. Karlsson, H., Samarasinghe, S., Ball, L.M., Sundberg, B., Lankester, A.C., Dazzi, F., Uzunel, M., Rao, K., Veys, P., Le Blanc, K., Ringdén, O. & Amrolia, P.J. (2008) Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood, 112, 532-541.
59. Kebriaei, P., Isola, L., Bahceci, E., Holland, K., Rowley, S., McGuirk, J., Devetten, M., Jansen, J., Herzig, R., Schuster, M., Monroy, R. & Uberti, J. (2009) Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 15, 804-811.
60. Klein, S.A., Bug, G., Mousset, S., Hofmann, W.K., Hoelzer, D. & Martin, H. (2011) Long term outcome of patients with steroid-refractory acute intestinal graft versus host disease after treatment with pentostatin. British Journal of Haematology, 154, 143-146.
61. Kobbe, G., Schneider, P., Rohr, U., Fenk, R., Neumann, F., Aivado, M., Dietze, L., Kronenwett, R., Hünerlitürkoglu, A. & Haas, R. (2001) Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplantation, 28, 47-49.
62. Krejci, M., Doubek, M., Buchler, T., Brychtova, Y., Vorlicek, J. & Mayer, J. (2005) Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Annals of Haematology, 84, 681-685.
63. Kulkarni, S., Powles, R., Sirohi, B., Treleaven, J., Saso, R., Horton, C., Atra, A., Ortin, M., Rudin, C., Goyal, S., Sankpal, S., Meller, S., Pinkerton, C.R., Mehta, J. & Singhal, S. (2003) Thalidomide after allogeneic haematopoietic stem cell transplantation:.activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplantation, 32, 165-170.
64. de Lavallade, H., Mohty, M., Faucher, C., Fürst, S., El-Cheikh, J. & Blaise, D. (2006) Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Haematologica, 91, 1438-1440.
65. Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M. & Ringdén, O. (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 363, 1439-1441.
66. Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M.E., Remberger, M., Dini, G., Egeler, R.M., Bacigalupo, A., Fibbe, W. & Ringdén, O. (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Developmental Committee of the European Group for Blood and Marrow Transplantation. Lancet, 371, 1579-1586.
67. Lee, S.J., Zahrieh, D., Agura, E., MacMillan, M.L., Maziarz, R.T., McCarthy, Jr, P.L., Ho, V.T., Cutler, C., Alyea, E.P., Antin, J.H. & Soiffer, R.J. (2004) Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood, 104, 1559-1564.
68. Levine, J.E., Paczesny, S., Mineishi, S., Braun, T., Choi, S.W., Hutchinson, R.J., Jones, D., Khaled, Y., Kitko, C.L., Bickley, D., Krijanovski, O., Reddy, P., Yanik, G. & Ferrara, J.L. (2008) Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood, 111, 2470-5.
69. Liu, J., Wang, H.X., Duan, L.N., Yang, H.M., Xue, M., Zhu, L., Ding, L. & Wang, Z.D. (2009) [Efficacy of anti-CD25 monoclonal antibody used in treating steroid-resistant acute graft-versus-host disease following haploidentical bone marrow transplantation.]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 17, 160-163.
70. MacMillan, M.L., Weisdorf, D.J., Wagner, J.E., DeFor, T.E., Burns, L.J., Ramsay, N.K., Davies, S.M. & Blazar, B.R. (2002a) Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant, 8, 387-394.
71. MacMillan, M.L., Weisdorf, D.J., Davies, S.M., DeFor, T.E., Burns, L.J., Ramsay, N.K., Wagner, J.E. & Blazar, B.R. (2002b) Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 8, 40-46.
72. Majumdar, M.K., Thiede, M.A., Haynesworth, S.E., Bruder, S.P. & Gerson, S.L. (2000) Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. Journal of Hematotherapy and Stem Cell Research, 9, 841-848.
73. Margolis, J. & Vogelsang, G. (2000) An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease. Seminars in Oncology, 27, 72-77.
74. Marshall, S.R. (2006) Technology insight: ECP for the treatment of GvHD-can we offer selective immune control without generalized immunosuppression? Nature Clinical Practice Oncology, 3, 302-314.
75. Martin, P.J., Schoch, G., Fisher, L., Byers, V., Anasetti, C., Appelbaum, F.R., Beatty, P.G., Doney, K., McDonald, G.B. & Sanders, J.E. (1990) A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood, 76, 1464-1472.
76. Martin, P.J., Uberti, J.P., Soiffer, R.J., Klingemann, H., Waller, E.K., Daly, A.S., Herrmann, R.P. & Kebriaei, P. (2010) Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial In GVHD. Biology of Blood and Marrow Transplantation, 16, S169-S170.
77. Martínez, C., Solano, C., Ferrá, C., Sampol, A., Valcárcel, D. & Pérez-Simón, J.A. Spanish Group for Stem Cell Transplantation (Grupo Español de Trasplante Hemopoyético y Terapia Celular) (2009) Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study. Biology of Blood and Marrow Transplantation, 15, 639-642.
78. Marty, F.M., Lee, S.J., Fahey, M.M., Alyea, E.P., Soiffer, R.J., Antin, J.H. & Baden, L.R. (2003) Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood, 102, 2768-2776.
79. Massenkeil, G., Rackwitz, S., Genvresse, I., Rosen, O., Dörken, B. & Arnold, R. (2002) Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplantation, 30, 899-903.
80. McDonald, G.B., Bouvier, M., Hockenbery, D.M., Stern, J.M., Gooley, T., Farrand, A., Murakami, C. & Levine, D.S. (1998) Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology, 115, 28-35.
81. Mielcarek, M., Storer, B.E., Boeckh, M., Carpenter, P.A., McDonald, G.B., Deeg, H.J., Nash, R.A., Flowers, M.E., Doney, K., Lee, S., Marr, K.A., Furlong, T., Storb, R., Appelbaum, F.R. & Martin, P.J. (2009) Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood, 113, 2888-2894.
82. Milner, L.A., Becker, M.W., Bernstein, S.H., Bruckner, L., Friedberg, J.W., Holland, G.A., Ifthikharuddin, J.J., Liesveld, J.L., Mathes, E.J., Menchel, H.L., Mullen, C.A., Sasson, T. & Phillips, G.L. 2nd (2011) Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease. American Journal of Hematology, 86, 712-714.
83. Nevo, S., Enger, C., Swan, V., Wojno, K.J., Fuller, A.K., Altomonte, V., Braine, H.G., Noga, S.J. & Vogelsang, G.B. (1999) Acute bleeding after allogeneic bone marrow transplantation: association with GvHD and effect on survival. Transplantation, 67, 681-689.
84. Onishi, C., Ohashi, K., Sawada, T., Nakano, M., Kobayashi, T., Yamashita, T., Akiyama, H. & Sakamaki, H. (2010) A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. International Journal of Hematology, 91, 464-470.
85. Oshrine, B., Lehmann, L.E. & Duncan, C.N. (2011) Safety and utility of liver biopsy after pediatric hematopoietic stem cell transplantation. Journal of Pediatric Hematology/Oncology, 33, 92-97.
86. Paczesny, S., Braun, T.M., Levine, J.E., Hogan, J., Crawford, J., Coffing, B., Olsen, S., Choi, S.W., Wang, H., Faca, V., Pitteri, S., Zhang, Q., Chin, A., Kitko, C., Mineishi, S., Yanik, G., Peres, E., Hanauer, D., Wang, Y., Reddy, P., Hanash, S. & Ferrara, J.L. (2010) Elafin is a biomarker of graft-versus-host disease of the skin. Science Translational Medicine, 2, 13ra2.
87. Patriarca, F., Sperotto, A., Damiani, D., Morreale, G., Bonifazi, F., Olivieri, A., Ciceri, F., Milone, G., Cesaro, S., Bandini, G., Dini, G., Corradini, P. & Fanin, R. (2004) Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica, 89, 1352-1359.
88. Pérez-Simon, J.A., López-Villar, O., Andreu, E.J., Rifón, J., Muntion, S., Campelo, M.D., Sánchez-Guijo, F.M., Martinez, C., Valcarcel, D. & Cañizo, C.D. (2011) Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica, 96, 1072-1076.
89. Perfetti, P., Carlier, P., Strada, P., Gualandi, F., Occhini, D., Van Lint, M.T., Ibatici, A., Lamparelli, T., Bruno, B., Raiola, A.M., Dominietto, A., Di Grazia, C., Bregante, S., Zia, S., Ferrari, G.M., Stura, P., Pogliani, E. & Bacigalupo, A. (2008) Extracorporeal photopheresis for the treatment of steroid refractory aGvHD. Bone Marrow Transplantation, 42, 609-617.
90. Perotti, C., Torretta, L., Viarengo, G., Roveda, L., Bernuzzi, S., Carbone, S., Del Fante, C., La Torre, R., Locatelli, F., Bonetti, F., Gabba, P., Bellosta, M. & Salvaneschi, L. (1999) Feasibility and safety of a new technique of extracorporeal photochemotherapy: experience of 240 procedures. Haematologica, 84, 237-241.
91. Perotti, C., Del Fante, C., Tinelli, C., Viarengo, G., Scudeller, L., Zecca, M., Locatelli, F. & Salvaneschi, L. (2010) Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion, 50, 1359-1369.
92. Perritt, D. (2006) Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 12, 7-12.
93. Pidala, J., Kim, J., Field, T., McBride, A., Kharfan-Dabaja, M., Perkins, J., Fernandez, H., Perez, L., Ayala, E. & Anasetti, C. (2009) Infliximab for managing steroid-refractory acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 15, 1116-1121.
94. Pidala, J., Kim, J., Roman-Diaz, J., Shapiro, J., Nishihori, T., Bookout, R., Anasetti, C. & Kharfan-Dabaja, M.A. (2010) Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Annals of Transplantation, 15, 21-29.
95. Pidala, J., Tomblyn, M., Nishihori, T., Field, T., Ayala, E., Perkins, J., Fernandez, H., Locke, F., Perez, L., Ochoa, L., Alsina, M. & Anasetti, C. (2011) Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica, 96, 1351-1356.
96. Piñana, J.L., Valcárcel, D., Martino, R., Moreno, M.E., Sureda, A., Briones, J., Brunet, S. & Sierra, J. (2006) Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 12, 1135-1141.
97. Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., Moorman, M.A., Simonetti, D.W., Craig, S. & Marshak, D.R. (1999) Multilineage potential of adult human mesenchymal stem cells. Science, 284, 143-147.
98. Ponec, R.J., Hackman, R.C. & McDonald, G.B. (1999) Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation. Gastrointestinal Endosccopy, 49, 612-621.
99. Prasad, V.K., Lucas, K.G., Kleiner, G.I., Talano, J.A., Jacobsohn, D., Broadwater, G., Monroy, R. & Kurtzberg, J. (2011) Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biology of Blood and Marrow Transplantation, 17, 534-541.
100. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J. & Thomas, E.D. (1995) 1994 consensus conference on AGvHD grading. Bone Marrow Transplantation, 15, 825-828.
101. Przepiorka, D., Kernan, N.A., Ippoliti, C., Papadopoulos, E.B., Giralt, S., Khouri, I., Lu, J.G., Gajewski, J., Durett, A., Cleary, K., Champlin, R., Andersson, B.S. & Light, S. (2000) Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood, 95, 83-89.
102. Rager, A., Frey, N., Goldstein, S.C., Reshef, R., Hexner, E.O., Loren, A., Luger, S.M., Perl, A., Tsai, D., Davis, J., Vozniak, M., Smith, J., Stadtmauer, E.A. & Porter, D.L. (2011) Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory aGvHD. Bone Marrow Transplantation, 46, 430-435.
103. Rao, K., Rao, A., Karlsson, H., Jagani, M., Veys, P. & Amrolia, P.J. (2009) Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease. Journal of Pediatric Hematology/Oncology, 31, 456-461.
104. Reddy, P. & Ferrara, J.L. (2003) Immunobiology of acute graft-versus-host disease. Blood Reviews, 17, 187-194.
105. Ross, W.A., Ghosh, S., Dekovich, A.A., Liu, S., Ayers, G.D., Cleary, K.R., Lee, J.H. & Couriel, D. (2008) Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies. American Journal of Gastroenterology, 103, 982-989.
106. Rowlings, P.A., Przepiorka, D., Klein, J.P., Gale, R.P., Passweg, J.R., Henslee-Downey, P.J., Cahn, J.Y., Calderwood, S., Gratwohl, A., Socié, G., Abecasis, M.M., Sobocinski, K.A., Zhang, M.J. & Horowitz, M.M. (1997) IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. British Journal of Haematology, 97, 855-864.
107. Roy, J., Snover, D., Weisdorf, S., Mulvahill, A., Filipovich, A. & Weisdorf, D. (1991) Simultaneous upper and lower endoscopic biopsy in the diagnosis of intestinal graft-versus-host disease. Transplantation, 51, 642-646.
108. Roy, J., McGlave, P.B., Filipovich, A.H., Miller, W.J., Blazar, B.R., Ramsay, N.K., Kersey, J.H. & Weisdorf, D.J. (1992) Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplantation, 10, 77-82.
109. Saliba, R.M., de Lima, M., Giralt, S., Andersson, B., Khouri, I.F., Hosing, C., Ghosh, S., Neumann, J., Hsu, Y., De Jesus, J., Qazilbash, M.H., Champlin, R.E. & Couriel, D.R. (2007) Hyperacute GvHD: risk factors, outcomes, and clinical implications. Blood, 109, 2751-2758.
110. Schmidt-Hieber, M., Fietz, T., Knauf, W., Uharek, L., Hopfenmüller, W., Thiel, E. & Blau, I.W. (2005) Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. British Journal of Haematology, 130, 568-574.
111. Schnitzler, M., Hasskarl, J., Egger, M., Bertz, H. & Finke, J. (2009) Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biology of Blood and Marrow Transplantation, 15, 910-918.
112. Shaughnessy, P.J., Bachier, C., Grimley, M., Freytes, C.O., Callander, N.S., Essell, J.H., Flomenberg, N., Selby, G. & Lemaistre, C.F. (2005) Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 11, 188-193.
113. Sieper, J. & Van Den Brande, J. (2005) Diverse effects of infliximab and etanercept on T lymphocytes. Seminars in Arthritis and Rheumatism, 34, 23-27.
114. Smith, E.P., Sniecinski, I., Dagis, A.C., Parker, P.M., Snyder, D.S., Stein, A.S., Nademanee, A., O'Donnell, M.R., Molina, A., Schmidt, G.M., Stepan, D.E., Kapoor, N., Niland, J.C. & Forman, S.J. (1998) Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Biology of Blood and Marrow Transplantation, 4, 27-37.
115. Snover, D.C., Weisdorf, S.A., Ramsay, N.K., McGlave, P. & Kersey, J.H. (1984) Hepatic GvHD: a study of the predictive value of liver biopsy in diagnosis. Hepatology, 4, 123-130.
116. Snover, D.C., Weisdorf, S.A., Vercellotti, G.M., Rank, B., Hutton, S. & McGlave, P. (1985) A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Human Pathology, 16, 387-392.
117. Srinivasan, R., Chakrabarti, S., Walsh, T., Igarashi, T., Takahashi, Y., Kleiner, D., Donohue, T., Shalabi, R., Carvallo, C., Barrett, A.J., Geller, N. & & Childs, R. (2004) Improved survival in steroid-refractory aGvHD after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. British Journal of Haematology, 124, 777-786.
118. Stelljes, M., Hermann, S., Albring, J., Köhler, G., Löffler, M., Franzius, C., Poremba, C., Schlösser, V., Volkmann, S., Opitz, C., Bremer, C., Kucharzik, T., Silling, G., Schober, O., Berdel, W.E., Schäfers, M. & Kienast, J. (2008) Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography. Blood, 111, 2909-2918.
119. Strasser, S.I., Shulman, H.M., Flowers, M.E., Reddy, R., Margolis, D.A., Prumbaum, M., Seropian, S.E. & McDonald, G.B. (2000) Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis. Hepatology, 32, 1265-1271.
120. Sullivan, K.M. (2004) Graft-vs-host disease. In: Thomas' Haematopoietic Cell Transplantation (ed. by K.G. Blume, S.J. Forman & F.R. Appelbaum), pp. 635-664. Blackwell Publishing Ltd, Oxford, UK.
121. Takami, A., Mochizuki, K., Okumura, H., Ito, S., Suga, Y., Yamazaki, H., Yamazaki, M., Kondo, Y., Asakura, H. & Nakao, S. (2006) Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. International Journal of Hematology, 83, 80-85.
122. Trzonkowski, P., Bieniaszewska, M., Juścińska, J., Dobyszuk, A., Krzystyniak, A., Marek, N., Myśliwska, J. & Hellmann, A. (2009) First-in-man clinical results of the treatment of patients with GvHD with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clinical Immunology, 133, 22-26.
123. Uberti, J.P., Ayash, L., Ratanatharathorn, V., Silver, S., Reynolds, C., Becker, M., Reddy, P., Cooke, K.R., Yanik, G., Whitfield, J., Jones, D., Hutchinson, R., Braun, T., Ferrara, J.L. & Levine, J.E. (2005) Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 11, 680-687.
124. Van Lint, M.T., Uderzo, C., Locasciulli, A., Majolino, I., Scimé, R., Locatelli, F., Giorgiani, G., Arcese, W., Iori, A.P., Falda, M., Bosi, A., Miniero, R., Alessandrino, P., Dini, G., Rotoli, B. & Bacigalupo, A. (1998) Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood, 92, 2288-2293.
125. Van Lint, M.T., Milone, G., Leotta, S., Uderzo, C., Scimè, R., Dallorso, S., Locasciulli, A., Guidi, S., Mordini, N., Sica, S., Cudillo, L., Fagioli, F., Selleri, C., Bruno, B., Arcese, W. & Bacigalupo, A. (2006) Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day + 5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood, 107, 4177-4181.
126. Varadi, G., Or, R., Slavin, S. & Nagler, A. (1996) In vivo CAMPATH-1 monoclonal antibodies: a novel mode of therapy for acute graft-versus-host disease. American Journal of Hematology, 52, 236-237.
127. Vogelsang, G.B., Lee, L. & Bensen-Kennedy, D.M. (2003) Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annual Review of Medicine, 54, 29-52.
128. Wandroo, F., Auguston, B., Cook, M., Craddock, C. & Mahendra, P. (2004) Successful use of Campath-1H in the treatment of steroid refractory liver GvHD. Bone Marrow Transplantation, 34, 285-287.
129. Wang, J.Z., Liu, K.Y., Xu, L.P., Liu, D.H., Chen, Y.H. & Huang, X.J. (2008) Chimeric anti-CD25 monoclonal antibody for treating acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Zhonghua Nei Ke Za Zhi, 47, 923-925.
130. Wang, J.Z., Liu, K.Y., Xu, L.P., Liu, D.H., Han, W., Chen, H., Chen, Y.H., Zhang, X.H., Zhao, T., Wang, Y. & Huang, X.J. (2011a) Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation. Transplant Proceedings, 43, 1928-1933.
131. Wang, Y., Xu, L.P., Liu, K.Y., Liu, D.H., Wang, J., Chen, H., Chen, Y.H., Han, W. & Huang, X.J. (2011b) Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of aGvHD: safety and feasibility. Bone Marrow Transplantation, 46, 892-898.
132. Weintraub, J.L., Belanger, A.R., Sung, C.C., Stangl, P.A., Nowakowski, F.S. & & Lookstein, R.L. (2010) Intra-arterial methylprednisolone infusion in treatment-resistant graft-versus-host disease. Cardiovascular Interventional Radiology, 33, 509-512.
133. Weisdorf, D., Haake, R., Blazar, B., Miller, W., McGlave, P., Ramsay, N., Kersey, J. & Filipovich, A. (1990) Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood, 75, 1024-1030.
134. Wolff, D., Roessler, V., Steiner, B., Wilhelm, S., Weirich, V., Brenmoehl, J., Leithaeuser, M., Hofmeister, N., Junghanss, C., Casper, J., Hartung, G., Holler, E. & Freund, M. (2005) Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplantation, 35, 1003-1010.
135. Wolff, D., Schleuning, M., von Harsdorf, S., Bacher, U., Gerbitz, A., Stadler, M., Ayuk, F., Kiani, A., Schwerdtfeger, R., Vogelsang, G.B., Kobbe, G., Gramatzki, M., Lawitschka, A., Mohty, M., Pavletic, S.Z., Greinix, H. & Holler, E. (2011) Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 17, 1-17.
136. Zhou, Y., Barnett, M.J. & Rivers, J.K. (2000) Clinical significance of skin biopsies in the diagnosis and management of graft-vs-host disease in early postallogeneic bone marrow transplantation. Archives of Dermatology, 136, 717-721.
137. Zidan, H., Lo, S., Wiebe, D., Talano, J. & Alemzadeh, R. (2008) Severe hypercholesterolemia mediated by lipoprotein X in a pediatric patient with chronic graft-versus-host disease of the liver. Pediatric Blood Cancer, 50, 1280-1281.